Breaking News

Top Stock Reports For Disney, Coca-Cola & Gilead

By Zacks Investment ResearchStock MarketsMay 21, 2019 02:18AM ET
Top Stock Reports For Disney, Coca-Cola & Gilead
By Zacks Investment Research   |  May 21, 2019 02:18AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Tuesday, May 21, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Coca-Cola (KO) and Gilead (GILD). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Disney’s shares have gained +28.7% over the past year, outperforming the Zacks Media Conglomerates industry’s gain of +23% during the same period. The Zacks analyst thinks Disney’s second-quarter fiscal 2019 top-line growth was driven by strong performance of DTCI and Parks, Experiences & Consumer Products segments. Higher guest spending and attendance and increase in consumer products business aided Parks segment revenues.

Additionally, Disney’s most-awaited movie, Avengers: Endgame, which recorded phenomenal box-office success, is expected to aid fiscal 2019 top line. However, second-quarter fiscal 2019 operating income decreased due to lower theatrical and home entertainment results and higher costs.

Increasing investments in ESPN and Disney+ and losses from streaming technology services hurt DTCI segment operating income. Moreover, due to the ongoing investments, Disney anticipates DTCI operating loss to be higher in third-quarter fiscal 2019.

(You can read the full research report on Disney here >>>).

Shares of Coca-Cola have increased +15.6% in the past year, outperforming the Zacks Soft Drinks Beverages industry which has gained +7.2% over the same period. The Zacks analyst thinks this is largely attributable to the effective execution of strategies to evolve as a consumer-centric total beverage company. This bolstered the company’s quarterly performances as evident from a robust surprise trend.

First-quarter 2019 marked its seventh positive earnings surprise in the last eight quarters and seventh straight sales beat. Top and bottom lines benefited from ongoing productivity efforts and disciplined growth strategies along with robust performance across all segments.

Further, innovation and investment in core categories and brands have been the key focus area for Coca-Cola, which has led to the expansion of retail value share. Its transformative global re-franchising initiatives are expected to boost margins. However, the company expects adverse currency rates to significantly hurt comparable revenues and operating income in the second quarter and 2019.

(You can read the full research report on Coca-Cola here >>>).

Buy-ranked Gilead’s shares have outperformed the Zacks Biotech industry year to date, gaining +5.3% vs. an increase of +0.3%. Although the sales miss was disappointing, Gilead’s earnings beat the consensus mark in the first quarter. Soft HCV franchise sales stabilized as compared to the levels in prior quarters.

The Zacks analyst thinks Gilead’s HIV franchise maintains momentum on continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. Meanwhile, it shifted focus to the HIV franchise, and newer avenues like CAR-T therapy and NASH. Gilead’s collaboration with Novo Nordisk (CO:NOVOb) for NASH treatments is a step in the right direction, given its recent debacles.

The company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. It is also developing a pipeline targeting inflammatory diseases. Data from phase III studies on filgotinib were also encouraging. A potential filing is planned by the end of this year.

(You can read the full research report on Gilead here >>>).

Other noteworthy reports we are featuring today include CME Group (CME), Concho Resources (NYSE:CXO) and Entergy (ETR).

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read
Featured Reports

Concho (CXO) Rides on RSP Permian Buyout, High Capex a Worry

The acquisition of RSP Permian has boosted Concho's scale and production prospects. However, high 2019 capex forecast of $2.9 billion may impact overall cash flows, per the Zacks analyst.

Project Investments Aid Entergy (ETR), High Debt Levels Hurt

Per the Zacks analyst, Entergy's disciplined investments in growth projects bolsters its prospects. However, massive debt levels can be a major headwind for the company going ahead.

Production from U.S. Resource Plays Boost Marathon (MRO)

Marathon Oil (NYSE:MRO) expects oil production from U.S. resource plays to rise 12% in 2019. However, the Zacks analyst is worried over the lack of clarity on dividend increase.

Favorable Budget, Solid Cash Flow Aid Leidos Holdings (LDOS)

Per the Zacks analyst, favorable U.S. budgetary amendments are boosting Ledios Holdings' growth.

Aqua America (WTR) to Gain from Acquisitions & Investments

Per the Zacks analyst, 64 acquisitions in the last five years and $1.4 billion investment in the 2019-2021 time frame to strengthen infrastructure will drive Aqua America's performance. (WIX) User Base Grows Wider, Spending on the Rise

According to the Zacks analyst, Wix is benefiting from product innovations and collaborations, favoring premium subscriber growth.

AGCO (AGCO) Rides on Strategic Investments, Improving Demand

The Zacks analyst expects AGCO to gain from improving global farm equipment demand and focus on strategic investments to expand product lines and improving factory productivity.

New Upgrades

Ubiquiti (UBNT) Buoyed by Strong Enterprise Technology Unit

Per the Zacks analyst, growth in global Enterprise Technology business driven by increasing market traction of UniFi products, including switches & security gateways, should drive Ubiquiti's top line.

New Strategic Acquisitions, Organic Growth Aid Bruker (BRKR)

The Zacks analyst is optimistic about buyouts of Hain, Mestrelab and Alicona Imaging which have started to contribute to the top line strongly. Series of product launches are driving organic growth.

Sturdy Global OAS Sales Lift Cardiovascular Systems (CSII)

The Zacks analyst is hopeful about Cardiovascular Systems gaining strong momentum internationally, banking on the commercial launch of orbital atherectomy system (OAS) in several geographies.

New Downgrades

Increasing Expenses Weigh On CME Group's (CME) Margins

Per the Zacks analyst, the company's expenses have been increasing for the past many years due to investment in technology and benefit expenses and are weighing on its margins.

Soaring Costs & Lower Vehicle Production Hurt Magna (MGA)

Per the Zacks analyst, elevated program launch costs and higher engineering spending to develop technology is impeding Magna's profit. Also, declining light vehicle production in key markets is a woe.

HRB Block (HRB) Grapples With Higher Expenses, Litigations

The Zacks analyst is worried about H&R Block (NYSE:HRB)'s rising expenses due to heavy investments in technology and operations. The company also faces litigation related to its various operating activities.

undefined undefined

Coca-Cola Company (The) (NYSE:KO): Free Stock Analysis Report

Gilead Sciences, Inc. (NASDAQ:GILD): Free Stock Analysis Report

Entergy Corporation (NYSE:ETR): Free Stock Analysis Report

The Walt Disney Company (NYSE:DIS): Free Stock Analysis Report

Concho Resources Inc. (CXO): Free Stock Analysis Report

CME Group Inc. (NASDAQ:CME): Free Stock Analysis Report

Original post

Zacks Investment Research
Top Stock Reports For Disney, Coca-Cola & Gilead
Top Stock Reports For Disney, Coca-Cola & Gilead

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email